Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
AssigneeVaccinex, Inc.
InventorsErnest S. Smith, Maurice Zauderer
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
Claims9
A method of decreasing blood brain barrier permeability in a subject with increased blood brain barrier permeability associated with a neuroinflammatory disorder selected from the group consisting of Amyotrophic Lateral Sclerosis, epilepsy, Alzheimer's Disease, Parkinson's Disease, and meningitis, comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, and wherein the antibody or antigen-binding fragment thereof specifically binds to semaphorin-4D (SEMA4D) and inhibits SEMA4D interaction with a SEMA4D receptor, and wherein administration of the antibody or antigen-binding fragment thereof maintains or increases Claudin-5 expression, thereby decreasing blood brain barrier permeability in the subject.
A method of increasing or maintaining Claudin-5 expression in a subject with increased blood brain barrier permeability associated with a neuroinflammatory disorder selected from the group consisting of Amyotrophic Lateral Sclerosis, epilepsy, Alzheimer's Disease, Parkinson's Disease, and meningitis, comprising diagnosing a subject with Amyotrophic Lateral Sclerosis, epilepsy, Alzheimer's Disease, Parkinson's Disease, or meningitis with increased blood brain barrier permeability, and administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, and wherein the antibody or antigen-binding fragment thereof specifically binds to semaphorin-4D (SEMA4D) and inhibits SEMA4D interaction with a SEMA4D receptor, and wherein administration of the antibody or antigen-binding fragment thereof maintains or increases Claudin-5 expression, thereby decreasing blood brain barrier permeability in the subject.
Dependencies are inferred from the claim text.